Cowen Reiterates Hold Rating for Aldeyra Therapeutics (ALDX)

Cowen reiterated their hold rating on shares of Aldeyra Therapeutics (NASDAQ:ALDX) in a report released on Monday, April 9th.

Other analysts have also issued reports about the stock. Canaccord Genuity restated a buy rating and set a $27.00 target price on shares of Aldeyra Therapeutics in a research note on Tuesday, March 13th. Seaport Global Securities restated a buy rating on shares of Aldeyra Therapeutics in a research report on Thursday, March 1st. Cantor Fitzgerald set a $23.00 price target on Aldeyra Therapeutics and gave the stock a buy rating in a report on Thursday, March 29th. ValuEngine raised Aldeyra Therapeutics from a sell rating to a hold rating in a report on Friday, February 2nd. Finally, Zacks Investment Research cut Aldeyra Therapeutics from a hold rating to a sell rating in a research report on Wednesday, April 4th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. Aldeyra Therapeutics currently has a consensus rating of Buy and a consensus price target of $16.93.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ ALDX opened at $7.05 on Monday. Aldeyra Therapeutics has a one year low of $3.80 and a one year high of $11.90. The company has a debt-to-equity ratio of 0.03, a quick ratio of 13.12 and a current ratio of 13.12.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings results on Thursday, March 29th. The biotechnology company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.04). equities research analysts predict that Aldeyra Therapeutics will post -1.59 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in Aldeyra Therapeutics by 3.2% during the 2nd quarter. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company’s stock worth $1,431,000 after acquiring an additional 9,407 shares during the period. Bank of New York Mellon Corp purchased a new stake in shares of Aldeyra Therapeutics during the third quarter valued at $134,000. 683 Capital Management LLC lifted its holdings in shares of Aldeyra Therapeutics by 59.1% during the third quarter. 683 Capital Management LLC now owns 835,514 shares of the biotechnology company’s stock valued at $6,016,000 after purchasing an additional 310,421 shares during the last quarter. Woodstock Corp raised its position in Aldeyra Therapeutics by 20.4% during the fourth quarter. Woodstock Corp now owns 58,243 shares of the biotechnology company’s stock valued at $396,000 after buying an additional 9,850 shares during the period. Finally, Geode Capital Management LLC raised its position in Aldeyra Therapeutics by 34.6% during the fourth quarter. Geode Capital Management LLC now owns 102,263 shares of the biotechnology company’s stock valued at $695,000 after buying an additional 26,269 shares during the period. Hedge funds and other institutional investors own 49.74% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was first reported by Week Herald and is the property of of Week Herald. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at https://weekherald.com/2018/04/20/aldeyra-therapeutics-aldx-receives-hold-rating-from-cowen.html.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.

Analyst Recommendations for Aldeyra Therapeutics (NASDAQ:ALDX)

Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply